治験一覧
8,963 件中 4681〜4700 件を表示
健康な非高齢者および高齢者を対象としたASP2151の安全性および薬物動態を評価するための研究
The objective of this study is to evaluate the safety and the pharmacokinetics of ASP2151 after multiple oral dosing of ASP2151 in healthy non-elderly male and elderly male Japanese subjects, and to compare the pharmacokinetics of ASP2151 in healthy non-elderly male and elderly male Japanese subjects.
軽度アルツハイマー病認知症患者を対象としたラナベセスタット（LY3314814）の研究
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
健康な中国人および日本人男性ボランティアにおけるBI 1026706の安全性、忍容性および薬物動態
Safety and tolerability of BI 1026706 in healthy Chinese and Japanese male subjects following oral administration of single rising doses (SRD) followed by multiple rising doses (MRD)
非感染性中間部ぶどう膜炎、後部ぶどう膜炎、または汎ぶどう膜炎患者におけるヒュミラ®の長期治療
This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
中等度から重度の活動性潰瘍性大腸炎（UC）患者を対象とした、ウパダシチニブ（ABT-494）の導入療法および維持療法における安全性と有効性を評価する研究
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.
中等度から重度の乾癬患者における有効性と安全性を評価する研究
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
LEO 80185ゲル（カルシポトリオール水和物＋ベタメタゾンプロピオン酸エステル）の日本人乾癬患者における試験
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
既治療転移性結腸直腸癌成人患者におけるナパブカシン（BBI-608）とFOLFIRIの併用療法に関する研究
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
局所進行性または転移性腫瘍における、チラゴルマブ単剤療法およびアテゾリズマブおよび／または他の抗がん剤との併用療法における、用量漸増時の安全性および薬物動態（PK）
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
補体阻害剤治療未経験の非定型溶血性尿毒症症候群（aHUS）の成人および青年患者を対象としたALXN1210の研究
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
非びらん性胃食道逆流症（NERD）の治療におけるTAK-438 10mgの第3相臨床試験
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).
小細胞肺癌患者におけるBMS-986012の研究
A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer
早期アルツハイマー病患者を対象としたエレベセスタット（E2609）の有効性および安全性を評価する24ヶ月間の研究
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
パーキンソン病患者におけるデュオドパ経腸液の特別使用成績調査
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage
再発性または難治性の末梢性T細胞リンパ腫（PTCL）患者における経口HBI-8000の有効性および安全性
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).
ASP1517の薬物動態を評価するための食事の影響に関する研究
The objective of this study is to evaluate the effect of food on the pharmacokinetics of a single oral dose of ASP1517 in non-elderly healthy adult male subjects.
クライオグローバルレジストリ
Cryo Global Registry a prospective, global, multi-center, observational Post-Market Registry
慢性呼吸不全患者におけるリハビリテーションを併用した鼻腔高流量酸素療法の有効性
The purpose of this study is to compare the exercise endurance between oxygen therapy with rehabilitation and nasal high flow therapy with rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.
HMAによる治療歴のあるMDSまたはCMMLの成人患者におけるグアデシタビン（SGI-110）と治療選択の比較
A Phase 3, randomized, open-label, parallel-group, multicenter study designed to evaluate the efficacy and safety of guadecitabine in participants with MDS or CMML who failed or relapsed after adequate prior treatment with azacitidine, decitabine, or both. This global study will be conducted in approximately 15 countries. Approximately 408 participants from approximately 100 study centers will be randomly assigned in a 2:1 ratio to either guadecitabine (approximately 272 participants) or Treatment Choice (approximately 136 participants). The study consists of a 21-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last more than 2 years, and the duration of individual participant participation will vary. Participants may continue to receive treatment for as long as they continue to benefit.
子宮筋腫に伴う疼痛症状の治療におけるレルゴリクス（TAK-385）40mgのプラセボ対照第3相試験
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.